Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672705 · ClinicalTrials.gov registry record · Phase 1
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
A Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT06672705 is a Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder that is actively recruiting participants, run by Timothy Voorhees. The registered enrollment target is 26 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06672705, a Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Timothy Voorhees.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and effective in treating patients with relapsed or refractory B-cell PTLD.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- BIOLOGICAL Epcoritamab
Study Locations (2)
Missouri
- Washington University - St Louis
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06672705
The ClinicalTrials.gov registry entry for NCT06672705 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Timothy Voorhees, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06672705 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT06672705 about?
NCT06672705 is a clinical study titled "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders". This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody,...
What is the current status of trial NCT06672705?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-06-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06672705 study?
This clinical trial studies the following conditions: Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT06672705?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06672705?
This trial is sponsored by Timothy Voorhees, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672705 being conducted?
This trial has 2 study locations across Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
EBV-Related Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
Missouri
All trials with a study site in Missouri
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.